Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the Cowen 41st Annual Health Care Conference, set for March 1-4, 2021. The company's CEO, Norbert Bischofberger, Ph.D., will contribute to a panel on "Novel Oncology Targets" on March 1 at 1:20 p.m. ET. Additionally, investor meetings are scheduled for March 2 and 3. Kronos Bio focuses on developing therapies targeting dysregulated transcription factors, with lead drug entospletinib aimed at NPM1-mutated acute myeloid leukemia, and KB-0742 for MYC-amplified solid tumors.
- None.
- None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.
Kronos Bio President and CEO Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion at the Monday, March 1, at 1:20 p.m. ET. The panel discussion will be available live to conference attendees. Members of the management team will also host meetings with investors on March 2 and March 3.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Company contact:
Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
syao@kronosbio.com
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
Media:
Sheryl Seapy
W2O
949-903-4750
sseapy@purecommunications.com
FAQ
What event is Kronos Bio participating in March 2021?
Who will represent Kronos Bio at the Cowen Conference?
What will be discussed at the panel featuring Kronos Bio's CEO?
What are the main therapies Kronos Bio is developing?
